Price
Financials
Consolidated, Rs crore| Mar 2026 | |
|---|---|
| Revenue from operations | 43 |
| Operating costs | 23 |
| EBITDA | 20 |
| EBITDA margin % | 46% |
| Depreciation & amortisation | 1 |
| Finance costs | 2 |
| Non-operating income | 0 |
| Pre-tax profit | 16 |
| Effective tax rate % | 27% |
| Profit after tax | 12 |
| Earnings per share (Rs) | 13.06 |
| Mar 2026 | |
|---|---|
| Revenue from operations | 43 |
| Operating costs | 23 |
| EBITDA | 20 |
| EBITDA margin % | 46% |
| Depreciation & amortisation | 1 |
| Finance costs | 2 |
| Non-operating income | 0 |
| Pre-tax profit | 16 |
| Effective tax rate % | 27% |
| Profit after tax | 12 |
| Earnings per share (Rs) | 13.06 |
| Paid out as dividend % | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | % | % | % | % | ||
| Profit CAGR | % | % | % | % | ||
| Share price CAGR | % | % | % | % | ||
| Average return on equity | % | % | % | 45% |
| Mar 2026 | |
|---|---|
| Net block (property, plant) | 17 |
| Capital work in progress | 0 |
| Investments | 0 |
| Current & other assets | 56 |
| Total assets | 73 |
| Share capital | 9 |
| Reserves & surplus | 17 |
| Total debt | 40 |
| Other liabilities & provisions | 7 |
| Equity + liabilities | 73 |
| Mar 2026 | |
|---|---|
| Operating cash flow | -6 |
| Investing cash flow | -2 |
| Free cash flow (after capex) | -8 |
| Financing cash flow | 8 |
| Net change in cash | 0 |
| Cash conversion (OCF / EBITDA) % | -9% |
| Mar 2026 | |
|---|---|
| Return on capital employed % | |
| Receivable days | 92 |
| Inventory days | 759 |
| Payable days | 116 |
| Cash cycle (days) | 735 |
| Working capital days | 300 |
| May 2026 | |
|---|---|
| Promoter group % | 67.70% |
| Foreign investors % | 0.29% |
| Domestic institutions % | 2.31% |
| Retail & others % | 29.71% |
| Shareholder count | 1,195 |
Fundamentals
Market value₹ 195 Cr.
Last price₹ 155
P/E (trailing)16.3
Book value / share₹
Return on capital%
Return on equity45.2 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)%
Profit CAGR (TTM)%
Consolidated figures.
Not enough published statements to compute ratios.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | BMLL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.3% | -2.8% | -2.6 pts |
| 1 month | +9.4% | -6.8% | +16.2 pts |
| 3 months | +13.2% | -7.6% | +20.9 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysSME scrip is not regularly traded
Quick answers
What is the market cap of Bio Medica Laboratories Ltd?
Bio Medica Laboratories Ltd (BMLL) has a market capitalisation of Rs 195 Cr. at the 2026-10-01 close.
What is the P/E ratio of Bio Medica Laboratories Ltd?
Bio Medica Laboratories Ltd trades at a P/E of 16.3 on trailing twelve-month profit, at the 2026-10-01 close.
What is the 52-week high and low of Bio Medica Laboratories Ltd?
The 52-week high is Rs 181.00 and the 52-week low is Rs 101.50.